Vogel, Arndt and Kasper, Stefan and Bitzer, Michael and Block, Andreas and Sinn, Marianne and Schulze-Bergkamen, Henning and Moehler, Markus and Pfarr, Nicole and Endris, Volker and Goeppert, Benjamin and Merx, Kirsten and Schnoy, Elisabeth and Siveke, Jens T. and Michl, Patrick and Waldschmidt, Dirk and Kuhlmann, Jan and Geissler, Michael and Kahl, Christoph and Evenkamp, Ralph and Schmidt, Torben and Kuhlmann, Alexander and Weichert, Wilko and Kubicka, Stefan (2018) PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. EUROPEAN JOURNAL OF CANCER, 92. pp. 11-19. ISSN 0959-8049, 1879-0852
Full text not available from this repository. (Request a copy)Abstract
Background: Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods: Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m(2) and gemcitabine 1000 mg/m(2) on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), overall survival (OS), and toxicity. In addition, a post hoc assessment of genetic alterations was performed. Finally, we performed a meta-analysis of trials with chemotherapy with and without EGFR antibodies. Results: Sixty-two patients were randomised in arm A and 28 patients in arm B. Patients received 7 treatment cycles in median (1-35) with a median treatment duration of 4.7 months (141 days, 8-765). PFS rate at 6 months was 54% in patients treated with cisplatin/gemcitabine and panitumumab but was 73% in patients treated with cisplatin/gemcitabine without antibody, respectively. Secondary end-points were an ORR of 45% in treatment arm A compared with 39% receiving treatment B and a median OS of 12.8 months (arm A) and of 20.1 months (arm B), respectively. In contrast to the p53-status, genetic alterations in IDH1/2 were linked to a high response after chemotherapy and prolonged survival. In accordance with our results, the meta-analysis of 12 trials did not reveal a survival advantage for patients treated with EGFR antibodies compared with chemotherapy alone. Conclusions: Panitumumab in combination with chemotherapy does not improve ORR, PFS and OS in patients with KRAS wild-type, advanced biliary cancer. Genetic profiling should be included in CCA trials to identify and validate predictive and prognostic biomarkers. (C) 2018 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRACT CANCER; METAANALYSIS; SURVIVAL; Bilary cancer; Chemotherapy; Panitumumab; Genetic profiling; KRAS; EGFR |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Mar 2020 09:52 |
| Last Modified: | 05 Mar 2020 09:52 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15002 |
Actions (login required)
 |
View Item |
